Top Markets
Coin of the day
Scandion Oncology A/S Scandion Oncology A/S

Scandion Oncology A/S

SCOL
Rangering i aksjer #40631
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S... Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Aksjekurs
$0.00045794
Sist synkronisert: 2025-07-11
Markedsverdi
$107.51K
Endring (1 dag)
-36.01%
Endring (1 år)
0.00%
Land
DK
Handel Scandion Oncology A/S (SCOL)

Kategori

P/S-forhold for Scandion Oncology A/S (SCOL)
P/S-forhold per 2026 TTM: 0
Ifølge Scandion Oncology A/S sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Scandion Oncology A/S fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE